Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides.
Amir PandiDavid AdamAmir ZareVan Tuan TrinhStefan L SchäferMarie BurtBjörn KlabundeElizaveta BobkovaManish KushwahaYeganeh ForoughijabbariPeter BraunChristoph SpahnChristian PreußerElke Pogge von StrandmannHelge B BodeHeiner von ButtlarWilhelm BertramsAnna Lena JungFrank AbendrothWilhelm BertramsGerhard HummerOlalla VázquezTobias J ErbPublished in: Nature communications (2023)
Bioactive peptides are key molecules in health and medicine. Deep learning holds a big promise for the discovery and design of bioactive peptides. Yet, suitable experimental approaches are required to validate candidates in high throughput and at low cost. Here, we established a cell-free protein synthesis (CFPS) pipeline for the rapid and inexpensive production of antimicrobial peptides (AMPs) directly from DNA templates. To validate our platform, we used deep learning to design thousands of AMPs de novo. Using computational methods, we prioritized 500 candidates that we produced and screened with our CFPS pipeline. We identified 30 functional AMPs, which we characterized further through molecular dynamics simulations, antimicrobial activity and toxicity. Notably, six de novo-AMPs feature broad-spectrum activity against multidrug-resistant pathogens and do not develop bacterial resistance. Our work demonstrates the potential of CFPS for high throughput and low-cost production and testing of bioactive peptides within less than 24 h.
Keyphrases
- cell free
- low cost
- deep learning
- high throughput
- molecular dynamics simulations
- circulating tumor
- multidrug resistant
- artificial intelligence
- big data
- convolutional neural network
- machine learning
- gram negative
- single cell
- healthcare
- amino acid
- public health
- molecular docking
- mental health
- drug resistant
- oxidative stress
- small molecule
- acinetobacter baumannii
- human health
- klebsiella pneumoniae